Form 4: Lantheus Holdings Director Sam R. Leno Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Sam R. Leno exercised stock options and sold shares of Lantheus Holdings, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 5th and 6th, 2024, Sam R. Leno, a director of Lantheus Holdings, Inc., engaged in transactions involving the company's common stock.
• Leno exercised stock options to acquire 2,045 shares on each day at a price of $16.30 per share.
• Concurrently, Leno sold shares on the open market at weighted average prices ranging from $62.12 to $65.44.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Leno directly owns 57,937 shares of Lantheus Holdings, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports transactions by a director under a pre-existing trading plan. There's no indication of positive or negative implications for the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the transactions are under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Insider transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. The use of a 10b5-1 plan suggests a pre-determined strategy for these transactions.

Comparison to Industry Standards

• It's common for executives at pharmaceutical and biotech companies like Lantheus to have stock option grants as part of their compensation packages.
• The exercise of options and subsequent sale of shares is a typical wealth management strategy.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, similar to practices at companies like GE Healthcare or Siemens Healthineers.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates